Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07456033 · ClinicalTrials.gov registry record · Phase 3
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
A Phase 3 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 456
- Enrollment target
NCT07456033: Recruiting Phase 3 study, sponsored by GlaxoSmithKline.
NCT07456033 is a Phase 3 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 456 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07456033, a Phase 3 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 456 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
Primary Outcome
A clinically significant exacerbation is defined as a worsening of asthma requiring the use of systemic corticosteroids.
Interventions
- DRUG Placebo
- DRUG Depemokimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 456 participants |
| Start Date | 2026-03-13 |
| Est. Completion | 2030-07-08 |
| Phase | Phase 3 |
What NCT07456033 shows while recruiting
NCT07456033 is an interventional study that assigns participants to a tested intervention. The registered 456 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07456033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07456033 about?
NCT07456033 is a clinical study titled "A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma". The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
What is the current status of trial NCT07456033?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 456 participants. The study started on 2026-03-13. Estimated completion is 2030-07-08.
What interventions are being tested in trial NCT07456033?
The interventions under investigation include: Placebo (DRUG), Depemokimab (DRUG).
Who is sponsoring clinical trial NCT07456033?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07456033's enrollment target sits among peer trials
456 827th of 2000 higher than 1,172 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04462302 · 456 participants · NA
An Internet-based Program to Help Cancer Survivors Manage Pain
- NCT05820919 · 456 participants · NA
Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase
- NCT06254612 · 456 participants · Phase 2
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
- NCT06457841 · 456 participants · NA
Stress and Resilience
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI